{"id":980955,"date":"2026-07-13T10:05:23","date_gmt":"2026-07-13T14:05:23","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/"},"modified":"2026-07-13T10:05:23","modified_gmt":"2026-07-13T14:05:23","slug":"clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/","title":{"rendered":"Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial"},"content":{"rendered":"<div class=\"mw_release\">\n<p>\n        <i>Principal Investigators of the Ongoing Phase I\/II a Trial Highlighted Positive Early Experience with Clearmind Medicine\u2019s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder<\/i>\n      <\/p>\n<p>Vancouver, Canada, July  13, 2026  (GLOBE NEWSWIRE) &#8212; Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems,\u00a0today provides key insights from its June 10 webinar, \u201cInside MEAI,\u201d during which the Company\u2019s CEO and the leading investigators of the Company\u2019s ongoing first-in-human clinical trial of CMND-100 (the \u201cTrial\u201d), provided an update based on their &#8220;hands-on&#8221; experience from the\u00a0 Trial.<\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WumfZvvnVFlVVtmUQoGjtXiKY6wbrsBPsfWBDQHKygMvop9GsOuo5G55tslkE4klHcCyC323t7mX8hegsim4e2fefK7A7XDYXRlqSa1gfRdmK4VVFHHnK7K7eW6Oglj8\" rel=\"nofollow\" target=\"_blank\">Watch the webinar here<\/a>.<\/p>\n<p>Based on the data available to date from the Trial, Dr. Anahita Bassir Nia of Yale School of Medicine and Dr. Jennifer Ellis of Johns Hopkins University have conveyed a generally positive impression of CMND\u2011100 and the ongoing Phase I\/IIa study.\u00a0 They highlighted the significant unmet need in Alcohol Use Disorder (AUD), where currently available treatments are limited in number and often accompanied by notable side effects.<\/p>\n<p>\n        <u>Key points emphasized by the investigators included:<\/u>\n      <\/p>\n<ul>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">The non-hallucinogenic profile of MEAI, which differentiates it from classical psychedelics. This could enable a much simpler and more accessible treatment model, without the need for hospitalization, intensive monitoring, or mandatory psychological\/psychiatric supervision.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">The reduced dependence on subjective psychedelic experiences improves blinding and allows for a clearer assessment of the compound\u2019s direct pharmacological effects.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">Recruitment has progressed well despite strict eligibility criteria for healthy volunteers.<\/li>\n<li style=\"margin-top:5pt;margin-bottom:5pt\">A promising early safety profile with no meaningful adverse effects or cardiac safety concerns observed to date.<\/li>\n<\/ul>\n<p>The session provided valuable insights into study design, dose escalation, pharmacokinetics, participant experience, and next steps, while underscoring that there is high potential for broader applications of MEAI beyond AUD where further research will be required.<\/p>\n<p>Dr. Adi Zuloff-Shani, CEO of Clearmind Medicine, stated: \u201cMuch of the progress and success we are seeing in this trial stems from our strategic choice of outstanding research partners. We are privileged to collaborate with two highly experienced and dedicated investigators, Dr. Bassir Nia and Dr. Ellis, at two of the world\u2019s leading medical centers. Their expertise and commitment together with our outstanding investigators from additional top-tier institutions, have been instrumental, and we are very pleased that our joint work to date has been smooth and productive. We believe these collaborations contribute to the groundbreaking research that drives our mission forward to deliver a meaningful new treatment option for patients suffering from alcohol use disorder.\u201d<\/p>\n<p>\n        <b>About\u00a0Clearmind\u00a0Medicine Inc.<\/b>\n      <\/p>\n<p>Clearmind is a clinical-stage\u00a0neuroplastogens\u00a0pharmaceutical biotech company focused on the discovery and development of non-hallucinogenic, second generation,\u00a0neuroplastogen-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements.<\/p>\n<p>The Company\u2019s intellectual portfolio currently consists of nineteen patent families, including 32 granted patents. The Company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.<\/p>\n<p>Shares of Clearmind are listed for trading on Nasdaq under the symbol\u00a0\u201cCMND.\u201d<\/p>\n<p>For further information, visit:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3FVpzyW0JRy60EOLwlK2xk8r6C3Uy67ax_jzE9h7e6pt6bmDH03rEmP2EiTVHX8lzIj3y9y4eQsd2-yV7n0OGhuh95JGfahuCRO5KH0gdl4lM24HgfKMFS_JfKXb9dmv\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/www.clearmindmedicine.com<\/u><\/a>\u00a0or contact:<\/p>\n<p>Investor Relations<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=nRk9u63EAyWrlDGi3HJfnovF20qM5JdLlVpMe_l1CKOg4txoD0LmMYcvqsvNidpwNXpecNhdlHjQUhN49pG2NEyXzvWI0BnO78pqPxFY1Nfj-B48XoqT7kZq0jQotOIx\" rel=\"nofollow\" target=\"_blank\"><u>invest@clearmindmedicine.com<\/u><\/a><br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wrunvtTZwd1LgDtgO6gTWlgamFxJrIs5-wq5THgQ3WhYGCKgcTfgTuahUeDvgfVmg9q4kVqw_W5tTuqG8S8sSqsbb8AIWbPKqn970-ve5whQbBFNytiRAN7uNzjXLzw0\" rel=\"nofollow\" target=\"_blank\"><u>www.Clearmindmedicine.com<\/u><\/a><\/p>\n<p>\n        <b>Forward-Looking Statements:<\/b>\n      <\/p>\n<p>This press release contains \u201cforward-looking statements\u201d within the meaning of the Private Securities Litigation Reform Act and other securities laws. Words such as \u201cexpects,\u201d \u201canticipates,\u201d \u201cintends,\u201d \u201cplans,\u201d \u201cbelieves,\u201d \u201cseeks,\u201d \u201cestimates\u201d and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses\u00a0the timing and progress of its clinical trial, that there is high potential for broader applications of MEAI beyond AUD where further research will be required and its belief that these collaborations contribute to the groundbreaking research that drives our mission forward to deliver a meaningful new treatment option for patients suffering from alcohol use disorder.\u00a0Forward-looking statements are not historical facts, and are based upon management\u2019s current expectations, beliefs and projections, many of which, by their nature, are inherently uncertain.\u00a0Such expectations, beliefs and projections are expressed in good faith.\u00a0However, there can be no assurance that management\u2019s expectations, beliefs and projections will be achieved, and actual results may differ materially from what is expressed in or indicated by the forward-looking statements. Forward-looking statements are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in the forward-looking statements. For a more detailed description of the risks and uncertainties affecting the Company, reference is\u00a0made to the Company\u2019s reports filed from time to time with the Securities and Exchange Commission (\u201cSEC\u201d), including, but not limited to, the risks detailed in the Company\u2019s annual report on Form 20-F for the fiscal year ended October 31,\u00a02025\u00a0and subsequent filings with the SEC. Forward-looking statements speak only as of the date the statements are made. The Company assumes no obligation to update forward-looking statements to reflect actual results, subsequent events or circumstances, changes in assumptions or changes in other factors affecting forward-looking information except to the extent required by applicable securities laws. If the Company does update one or more forward-looking statements, no inference should be drawn that the Company will make additional updates with respect thereto or with respect to other forward-looking statements. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Clearmind is not responsible for the contents of third-party websites.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MTA3NiM3NzAyOTk0IzUwMDA4NjkzNA==\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NmFmZTAxNjUtNmIyZS00YWIzLTk2NDItZTJlMTlmYmJlMmUzLTUwMDA4NjkzNC0yMDI2LTA3LTEzLWVu\/tiny\/Clearmind-Medicine-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Principal Investigators of the Ongoing Phase I\/II a Trial Highlighted Positive Early Experience with Clearmind Medicine\u2019s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder Vancouver, Canada, July 13, 2026 (GLOBE NEWSWIRE) &#8212; Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems,\u00a0today provides key insights from its June 10 webinar, \u201cInside MEAI,\u201d during which the Company\u2019s CEO and the leading investigators of the Company\u2019s ongoing first-in-human clinical trial of CMND-100 (the \u201cTrial\u201d), provided an update based on their &#8220;hands-on&#8221; experience from the\u00a0 Trial. Watch the webinar here. Based on the data available to date from the Trial, Dr. Anahita &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-980955","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v28.0 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Principal Investigators of the Ongoing Phase I\/II a Trial Highlighted Positive Early Experience with Clearmind Medicine\u2019s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder Vancouver, Canada, July 13, 2026 (GLOBE NEWSWIRE) &#8212; Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems,\u00a0today provides key insights from its June 10 webinar, \u201cInside MEAI,\u201d during which the Company\u2019s CEO and the leading investigators of the Company\u2019s ongoing first-in-human clinical trial of CMND-100 (the \u201cTrial\u201d), provided an update based on their &#8220;hands-on&#8221; experience from the\u00a0 Trial. Watch the webinar here. Based on the data available to date from the Trial, Dr. Anahita &hellip; Continue reading &quot;Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-13T14:05:23+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MTA3NiM3NzAyOTk0IzUwMDA4NjkzNA==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial\",\"datePublished\":\"2026-07-13T14:05:23+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/\"},\"wordCount\":946,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MTA3NiM3NzAyOTk0IzUwMDA4NjkzNA==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/\",\"name\":\"Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MTA3NiM3NzAyOTk0IzUwMDA4NjkzNA==\",\"datePublished\":\"2026-07-13T14:05:23+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MTA3NiM3NzAyOTk0IzUwMDA4NjkzNA==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTc2MTA3NiM3NzAyOTk0IzUwMDA4NjkzNA==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/","og_locale":"en_US","og_type":"article","og_title":"Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Market Newsdesk","og_description":"Principal Investigators of the Ongoing Phase I\/II a Trial Highlighted Positive Early Experience with Clearmind Medicine\u2019s Non-Hallucinogenic MEAI Compound for Alcohol Use Disorder Vancouver, Canada, July 13, 2026 (GLOBE NEWSWIRE) &#8212; Clearmind Medicine Inc. (Nasdaq: CMND) (\u201cClearmind\u201d or the \u201cCompany\u201d), a clinical-stage biotech company focused on the discovery and development of novel, non-hallucinogenic, second generation, neuroplastogen-derived therapeutics to solve major under-treated health problems,\u00a0today provides key insights from its June 10 webinar, \u201cInside MEAI,\u201d during which the Company\u2019s CEO and the leading investigators of the Company\u2019s ongoing first-in-human clinical trial of CMND-100 (the \u201cTrial\u201d), provided an update based on their &#8220;hands-on&#8221; experience from the\u00a0 Trial. Watch the webinar here. Based on the data available to date from the Trial, Dr. Anahita &hellip; Continue reading \"Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/","og_site_name":"Market Newsdesk","article_published_time":"2026-07-13T14:05:23+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MTA3NiM3NzAyOTk0IzUwMDA4NjkzNA==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial","datePublished":"2026-07-13T14:05:23+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/"},"wordCount":946,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MTA3NiM3NzAyOTk0IzUwMDA4NjkzNA==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/","name":"Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MTA3NiM3NzAyOTk0IzUwMDA4NjkzNA==","datePublished":"2026-07-13T14:05:23+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MTA3NiM3NzAyOTk0IzUwMDA4NjkzNA==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTc2MTA3NiM3NzAyOTk0IzUwMDA4NjkzNA=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/clearmind-shares-promising-real-world-insights-from-ongoing-cmnd-100-first-in-human-trial\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Clearmind Shares Promising Real-World Insights from Ongoing CMND-100 First-in-Human Trial"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/980955","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=980955"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/980955\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=980955"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=980955"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=980955"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}